Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TVF Communications

- PMLiVE

NEW WEBINAR! From Clicks to Outcomes: Measuring the Impact of Your Medical Education Platform

Struggling to quantify the value of your medical education platform and prove its ROI? Join our upcoming Pharma-exclusive webinar to learn real-work strategies and tips for developing a Med Ed...

Impetus Digital

- PMLiVE

World Kidney Day – Boehringer launches CKD initiative to tackle UK health inequalities

Approximately 10% of the UK population is affected by chronic kidney disease

Biogen Idec building

Biogen initiates phase 3 study of felzartamab in kidney transplant patients

The trial will evaluate the candidate in patients with antibody-mediated rejection

- PMLiVE

NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis

Around 1,000 patients could benefit from the relugolix combination therapy every year

- PMLiVE

Roche and Zealand partner on mid-stage obesity candidate in deal worth $5.3bn

The companies will develop petrelintide as both a standalone therapy and in combination with Roche’s CT-388

- PMLiVE

Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

The neurological disorder affects more than 150,000 people in the UK

- PMLiVE

Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis

The inflammatory skin disease affects up to 20% of children and 10% of adults worldwide

- PMLiVE

Novartis gains rights to Kyorin’s chronic spontaneous urticaria candidate in deal worth $830m

The common skin condition affects approximately 40 million people worldwide

- PMLiVE

Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA

Over 11,000 people in the UK are affected by the rare genetic disease

- PMLiVE

J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme

More than 125 million people worldwide are estimated to be living with the immune-mediated skin disease

- PMLiVE

Michelle Worst Honored With 2025 HOPA Volunteer Award

Medscape is proud to highlight Michelle A. Worst, PharmD, BCOP, MBA, CHCP, Senior Director and Team Lead of Clinical Strategy in Hematology/Oncology, for her well-deserved recognition as the recipient of...

Medscape Education

- PMLiVE

BMS granted EC approval for immunotherapy combination in liver cancer

More than 866,100 cases of the disease were diagnosed globally in 2022

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links